Diabetes and macrovascular disease

被引:103
作者
Vinik, A
Flemmer, M
机构
[1] Virginia Med Sch, Norfolk, VA 23510 USA
[2] Leonard R Strelitz Diabet Inst, Norfolk, VA 23510 USA
关键词
diabetes; macrovascular events; clopidogrel;
D O I
10.1016/S1056-8727(01)00212-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in patients with diabetes. Macrovascular events, including stroke, myocardial infarction (MI), and peripheral arterial disease (PAD), occur earlier than in nondiabetics and the underlying pathologies are often more diffuse and severe. Diabetic arteriopathy, which encompasses endothelial dysfunction, hypercoagulability, changes in blood flow, and platelet abnormalities, contributes to the early evolution of these events. Tight glucose and blood pressure control improves the vascular status of these patients by varying degrees. Antiplatelet agents have also been shown to be effective in the secondary prevention of cardiovascular events. In the ideal world, every risk factor would be addressed and each diabetic would have excellent glycemic control, a low normal blood pressure, a low LDL, and be prescribed an ACE inhibitor, together with aspirin and clopidogrel. If this is done, this emerging epidemic of macrovascular disease will be contained. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:235 / 245
页数:11
相关论文
共 89 条
[1]   EPIDEMIOLOGY OF SOME PERIPHERAL ARTERIAL FINDINGS IN DIABETIC MEN AND WOMEN - EXPERIENCES FROM THE FRAMINGHAM-STUDY [J].
ABBOTT, RD ;
BRAND, FN ;
KANNEL, WB .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (04) :376-381
[2]  
Alderman EL, 1996, NEW ENGL J MED, V335, P217
[3]   Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes [J].
Alexander, JH ;
Harrington, RA ;
Tuttle, RH ;
Berdan, LG ;
Lincoff, AM ;
Deckers, JW ;
Simoons, ML ;
Guerci, A ;
Hochman, JS ;
Wilcox, RG ;
Kitt, MM ;
Eisenberg, PR ;
Califf, RM ;
Topol, EJ ;
Karsh, K ;
Ruzyllo, W ;
Stepinska, J ;
Widimsky, P ;
Boland, JB ;
Armstrong, PW .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (08) :1147-1151
[4]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[5]  
*AM DIAB ASS, 2000, DIAB FACTS FIG 2000
[6]  
*AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS33
[7]  
*AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS62
[8]  
[Anonymous], 1995, Br. Med. J, DOI DOI 10.1136/BMJ.310.6972.83
[9]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[10]  
[Anonymous], 2000, Lancet, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7